Akeso Drug Fails FDA Review; Chinaamc HK Biotech ETF (03069.HK) -2.22%
- As of 9:42 on November 18, Chinaamc HK Biotech ETF (03069.HK) fell 2.22% intraday to a latest price of HK$14.070, with a turnover of HK$3.31 million.
- The ETF tracks the Hang Seng Hong Kong-Listed Biotech Index under a full replication strategy, with a management fee of 0.40% and assets under management of HK$3.71 billion.
- Akeso's ivonescimab application received a US FDA complete response letter and was not approved; its shares fell 22% on November 16.
NewTimeSpace News: As of 9:42 on November 18, 2026, Chinaamc HK Biotech ETF (03069.HK) fell 2.22% intraday to a latest price of HK$14.070, with a turnover of HK$3.31 million, a trading volume of 233,400 shares, and a turnover rate of 0.09%. Its current net asset value per unit is HK$14.3709, and its assets under management stand at HK$3.71 billion.
NewTimeSpace understands that Chinaamc HK Biotech ETF (03069.HK) is managed by China Asset Management (Hong Kong), with the full name ChinaAMC Hang Seng Biotech ETF, and an investment objective of providing investment returns that closely track the Hang Seng Hong Kong-Listed Biotech Index, before fees and expenses. The ETF primarily adopts a full replication strategy, investing directly in securities within the Index in weightings broadly the same as their weightings in the Index; where restrictions or limited availability prevent the purchase of certain constituents, it will adopt a representative sampling strategy, under which the maximum deviation of any constituent from its Index weighting does not exceed 4%. The ETF may invest up to 5% of net asset value in money market instruments and cash deposits for cash management purposes; non-constituent securities held as a result of corporate actions by Index constituents are capped at 10% of net asset value; and it currently has no intention to use financial derivative instruments for hedging or investment purposes. The fund was established and listed on the Stock Exchange of Hong Kong on March 18, 2021, with a management fee of 0.40%. As of November 17, the ETF had assets under management of HK$3.71 billion and a net asset value per unit of HK$14.3709.
On the news front, Summit, the overseas partner of Akeso (09926.HK), announced on November 15 that it had received a complete response letter from the US Food and Drug Administration for the marketing application of ivonescimab (AK112, a PD-1/VEGF bispecific) combined with platinum-based chemotherapy; the application was not approved, for the indication of non-squamous non-small cell lung cancer progressing after EGFR-TKI therapy. According to Cailian Press, the dispute in the complete response letter centres on overall survival data. Akeso shares closed down 22% on November 16, and the Hang Seng Biotech Index fell 2.21% that day.
In its November 18 healthcare sector weekly, Everbright Securities noted that with the dual medical insurance catalogues in place, the policy path for innovative drugs from hospital access to reimbursement has been fully opened; the 2026 national reimbursement list adds 107 drugs, 51 of them Class 1 innovative drugs, while the commercial health insurance innovative drug list expands to 28, and both take effect on January 1, 2027.
- JD Q3 Revenue Up 3.5%; Tracker Fund of HK (02800.HK) -0.68%
- Nvidia Q3 Sales Top $100bn; Csop HK-Korea Tech+ ETF (03431.HK) +0.82%
- HBM HOLDINGS-B (02142.HK): CRHX-101 Spin-Off Targets Nasdaq Listing
- LINK TOUCH: Closes RMB 100M-Level D3 Round With 14 Investors
- DENGLIN TECH-P (09917.HK): Nine-Month Revenue Tops RMB 500 Million